Last reviewed · How we verify
Thymosin Alpha
Thymosin Alpha is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activation of immune cells.
Thymosin Alpha is an immunomodulatory peptide that enhances T-cell maturation and immune function by promoting thymic development and activation of immune cells. Used for Immunodeficiency disorders, Chronic hepatitis B, Cancer immunotherapy adjunct.
At a glance
| Generic name | Thymosin Alpha |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Immunomodulator |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Thymosin Alpha is a naturally occurring peptide derived from thymic tissue that acts as an immunomodulator. It stimulates the differentiation and maturation of T-lymphocytes in the thymus and enhances overall immune cell function, including activation of macrophages and natural killer cells. This mechanism makes it useful in conditions characterized by immune deficiency or impaired immune response.
Approved indications
- Immunodeficiency disorders
- Chronic hepatitis B
- Cancer immunotherapy adjunct
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma (PHASE2)
- A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer (PHASE2)
- Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI) (NA)
- The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC (PHASE2)
- Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients (PHASE2)
- A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer (PHASE2)
- Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine (PHASE1)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymosin Alpha CI brief — competitive landscape report
- Thymosin Alpha updates RSS · CI watch RSS
- Second Affiliated Hospital, School of Medicine, Zhejiang University portfolio CI